These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 20230544)

  • 1. Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer.
    Eton DT; Shevrin DH; Beaumont J; Victorson D; Cella D
    Value Health; 2010 Aug; 13(5):613-23. PubMed ID: 20230544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
    Rago RP; Einstein A; Lush R; Beer TM; Ko YJ; Henner WD; Bubley G; Merica EA; Garg V; Ette E; Harding MW; Dalton WS
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):297-305. PubMed ID: 12721757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study.
    Berthold DR; Pond GR; Roessner M; de Wit R; Eisenberger M; Tannock AI;
    Clin Cancer Res; 2008 May; 14(9):2763-7. PubMed ID: 18451243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.
    Armstrong AJ; Garrett-Mayer E; Ou Yang YC; Carducci MA; Tannock I; de Wit R; Eisenberger M
    J Clin Oncol; 2007 Sep; 25(25):3965-70. PubMed ID: 17761981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
    Canil CM; Moore MJ; Winquist E; Baetz T; Pollak M; Chi KN; Berry S; Ernst DS; Douglas L; Brundage M; Fisher B; McKenna A; Seymour L
    J Clin Oncol; 2005 Jan; 23(3):455-60. PubMed ID: 15659491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
    Zhang HL; Ye DW; Yao XD; Dai B; Zhang SL; Shen YJ; Zhu Y; Zhang W
    Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prednisone monotherapy in asymptomatic hormone refractory prostate cancer.
    Heng DY; Chi KN
    Can J Urol; 2006 Dec; 13(6):3335-9. PubMed ID: 17187697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life in advanced prostate cancer and its treatments: biochemical failure and metastatic disease populations.
    Sartor O; Flood E; Beusterien K; Park J; Webb I; MacLean D; Wong BJ; Mark Lin H
    Clin Genitourin Cancer; 2015 Apr; 13(2):101-12. PubMed ID: 25262852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer.
    Berry WR
    Urology; 2005 Jun; 65(6 Suppl):2-7. PubMed ID: 15939076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
    de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
    Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
    Saad F; Ruether D; Ernst S; North S; Cheng T; Perrotte P; Karakiewicz P; Winquist E;
    BJU Int; 2008 Aug; 102(5):551-5. PubMed ID: 18510661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hormone-refractory metastatic prostate carcinoma -- combination improves survival].
    Aktuelle Urol; 2005 Sep; 36(5):385-7. PubMed ID: 16163602
    [No Abstract]   [Full Text] [Related]  

  • 13. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.
    Van Poppel H
    Can J Urol; 2005 Feb; 12 Suppl 1():81-5. PubMed ID: 15780173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.
    Sava T; Basso U; Porcaro A; Cetto GL
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):53-62. PubMed ID: 15757438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.
    Chi KN; Gleave ME; Klasa R; Murray N; Bryce C; Lopes de Menezes DE; D'Aloisio S; Tolcher AW
    Clin Cancer Res; 2001 Dec; 7(12):3920-7. PubMed ID: 11751483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapy of hormone refractory prostate carcinoma with mitoxantrone. A clinical phase II study].
    Otto T; Rembrink K; Goepel M; Krege S; Meyer-Schwiekerath M; Rübben H
    Urologe A; 1996 Mar; 35(2):142-5. PubMed ID: 8650848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
    Hussain M; Tangen CM; Lara PN; Vaishampayan UN; Petrylak DP; Colevas AD; Sakr WA; Crawford ED;
    J Clin Oncol; 2005 Dec; 23(34):8724-9. PubMed ID: 16314632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
    Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
    J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?
    Oudard S; Banu E; Medioni J; Scotte F; Banu A; Levy E; Wasserman J; Kacso G; Andrieu JM
    BJU Int; 2009 Jun; 103(12):1641-6. PubMed ID: 19210673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitoxantrone, vinorelbine and prednisone (MVD) in the treatment of metastatic hormonoresistant prostate cancer--a phase II trial.
    Bernardi D; Talamini R; Zanetti M; Simonelli C; Vaccher E; Spina M; Tirelli U
    Prostate Cancer Prostatic Dis; 2004; 7(1):45-9. PubMed ID: 14999238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.